• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

GEDi Cube, Renovaro Biosciences Announce Intention to Merge

News
Article

Companies hope to accelerate fight against cancer

Health care and medical background image made with Generative AI. Image Credit: Adobe Stock Images/Orange Square

Image Credit: Adobe Stock Images/Orange Square

GEDi Cube, an artificial intelligence (AI) company, and Renovaro Biosciences, a pre-clinical biotechnology organization, have revealed an exclusive letter of intent to merge into a single entity. As part of a potential merger, the focus would be on accelerating diagnosis, enhancing treatment effectiveness, discovering new therapies, and expanding access to life-saving technologies for cancer and other diseases.

"We are rapidly expanding our technologies to include other cancers and diseases," said Craig Rhodes, CEO, GEDi Cube, in a company press release. "I believe that uniting with Renovaro BioSciences’ potential solid tumor therapies is not merely synergistic. It could also create a multiplier effect to expedite diagnosis, improve treatment outcomes and discover, in silico, new therapies to improve many lives.”

Reference: AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer. Business Wire. August 9, 2023. Accessed August 10, 2023. https://www.businesswire.com/news/home/20230809952021/en/AI-Company-GEDi-Cube-and-Renovaro-Biosciences-Announce-a-Binding-Exclusive-Letter-of-Intent-to-Merge-Accelerating-Fight-Against-Cancer

Recent Videos
Related Content